Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

Open access
Sandireddy, Reddemma, Sakthivel, Suganya, Gupta, Priyanka, Behari, Jatin, Tripathi, Madhulika, Singh, Brijesh Kumar·2024·Frontiers in Cell and Developmental Biology

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is the most common liver disorder worldwide, with an estimated global prevalence of more than 31%. Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a progressive form of MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide a comprehensive analysis of the extrahepatic manifestations of MASH, focusing on chronic diseases related to the cardiovascular, muscular, and renal systems. A systematic review of published studies and literature was conducted to summarize the findings related to the systemic impacts of MASLD and MASH. The review focused on the association of MASLD and MASH with metabolic comorbidities, cardiovascular mortality, sarcopenia, and chronic kidney disease. Mechanistic insights into the concept of lipotoxic inflammatory “spill over” from the MASH-affected liver were also explored. MASLD and MASH are highly associated (50%–80%) with other metabolic comorbidities such as impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, and hypertension. Furthermore, more than 90% of obese patients with type 2 diabetes have MASH. Data suggest that in middle-aged individuals (especially those aged 45–54), MASLD is an independent risk factor for cardiovascular mortality, sarcopenia, and chronic kidney disease. The concept of lipotoxic inflammatory “spill over” from the MASH-affected liver plays a crucial role in mediating the systemic pathological effects observed. Understanding the multifaceted impact of MASH on the heart, muscle, and kidney is crucial for early detection and risk stratification. This knowledge is also timely for implementing comprehensive disease management strategies addressing multi-organ involvement in MASH pathogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2024.1433857

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 188

  1. Alonso-Pena, 2023, Innovative therapeutic approaches in non-alcoholic fatty liver disease: when knowing your patient is key, Int. J. Mol. Sci., 24, 10718, 10.3390/ijms241310718 · DOI
  2. Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆), J. Hepatol., 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
  3. Arslan, 2020, Relationship between non-alcoholic fatty liver disease and coronary heart disease, World J. Clin. Cases., 8, 4688, 10.12998/wjcc.v8.i20.4688 · DOI
  4. Ballestri, 2014, Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease, World J. Gastroenterol., 20, 1724, 10.3748/wjg.v20.i7.1724 · DOI · Paper page
  5. Barreto, 2009, Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients, Clin. J. Am. Soc. Nephrol., 4, 1551, 10.2215/CJN.03980609 · DOI · Paper page
  6. Berezin, 2023, Cardiac hepatopathy: new perspectives on old problems through a prism of endogenous metabolic regulations by hepatokines, Antioxidants (Basel), 12, 516, 10.3390/antiox12020516 · DOI
  7. Bhanji, The long winding road to transplant: how sarcopenia and debility impact morbidity and mortality on the waitlist, Clin. Gastroenterol. Hepatol., 15, 1492, 10.1016/j.cgh.2017.04.004 · DOI
  8. Bhanji, Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis, Hepatology, 66, 2055, 10.1002/hep.29420 · DOI · Paper page
  9. Bian, 2013, CCN1 expression in hepatocytes contributes to macrophage infiltration in nonalcoholic fatty liver disease in mice, J. Lipid. Res., 54, 44, 10.1194/jlr.M026013 · DOI
  10. Bilson, 2023, Steatotic liver disease, MASLD and risk of chronic kidney disease, Diabetes. Metab., 50, 101506, 10.1016/j.diabet.2023.101506 · DOI · Paper page
  11. Boesch, 2023, Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH, J. Hepatol., 80, 397, 10.1016/j.jhep.2023.10.039 · DOI
  12. Brody, 2020, The gut microbiome, Nature, 577, S5, 10.1038/d41586-020-00194-2 · doi:10.1038/d41586-020-00194-2
  13. Byrne, 2013, Ectopic fat, insulin resistance and non-alcoholic fatty liver disease, Proc. Nutr. Soc., 72, 412, 10.1017/S0029665113001249 · DOI
  14. Camici, 2007, Coronary microvascular dysfunction, N. Engl. J. Med., 356, 830, 10.1056/NEJMra061889 · DOI · Paper page
  15. Cao, 2021, The association between NAFLD and risk of chronic kidney disease: a cross-sectional study, Ther. Adv. Chronic. Dis., 12, 20406223211048649, 10.1177/20406223211048649 · DOI
  16. Castillo-Rodriguez, 2018, Impact of altered intestinal microbiota on chronic kidney disease progression, Toxins (Basel), 10, 300, 10.3390/toxins10070300 · DOI
  17. Chakravarthy, 2020, Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis, Front. Endocrinol. (Lausanne), 11, 592373, 10.3389/fendo.2020.592373 · DOI
  18. Chang, 2019, Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography, Echocardiography, 36, 1290, 10.1111/echo.14400 · DOI
  19. Chaudhry, 2019, Immune cell trafficking to the liver, Transplantation, 103, 1323, 10.1097/TP.0000000000002690 · DOI
  20. Choe, 2024, Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up, Metabolism, 153, 155800, 10.1016/j.metabol.2024.155800 · DOI
  21. Cusi, 2024, From NAFLD to MASLD: promise and pitfalls of a new definition †, Hepatology, 79, E13, 10.1097/HEP.0000000000000706 · DOI
  22. Deacon, 2011, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review, Diabetes. Obes. Metab., 13, 7, 10.1111/j.1463-1326.2010.01306.x · DOI · Paper page
  23. Del, 2021, Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review, J. Am. Coll. Cardiol., 78, 1352, 10.1016/j.jacc.2021.07.042 · DOI · Paper page
  24. Delgado-Marin, 2024, Indoxyl sulfate-induced valve endothelial cell endothelial-to-mesenchymal transition and calcification in an integrin-linked kinase-dependent manner, Cells, 13, 481, 10.3390/cells13060481 · doi:10.3390/cells13060481
  25. Dhindsa, 2018, Hypogonadotropic hypogonadism in men with diabesity, Diabetes .Care., 41, 1516, 10.2337/dc17-2510 · DOI · Paper page
  26. Dimitroglou, 2023, Novel anti-inflammatory therapies in coronary artery disease and acute coronary syndromes, Life (Basel), 13, 1669, 10.3390/life13081669 · DOI
  27. Duan, 2022, Association of inflammatory cytokines with non-alcoholic fatty liver disease, Front. Immunol., 13, 880298, 10.3389/fimmu.2022.880298 · DOI · Paper page
  28. Ebert, 2014, Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus, J. Clin. Endocrinol. Metab., 99, E2510, 10.1210/jc.2013-4349 · DOI
  29. Estes, 2020, Modelling NAFLD disease burden in four Asian regions-2019-2030, Aliment. Pharmacol. Ther., 51, 801, 10.1111/apt.15673 · DOI · Paper page
  30. Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatol., 67, 123, 10.1002/hep.29466 · DOI · Paper page
  31. Fan Xz, 2024, Systemic metabolic Abnormalities: key drivers of complications and mortality in MASLD, J. Hepatol., 80, e246, 10.1016/j.jhep.2024.02.001 · DOI
  32. Frontera, 2015, Skeletal muscle: a brief review of structure and function, Calcif. Tissue. Int., 96, 183, 10.1007/s00223-014-9915-y · DOI · Paper page
  33. Ganz, 2012, Hepcidin and iron homeostasis, Biochim. Biophys. Acta., 1823, 1434, 10.1016/j.bbamcr.2012.01.014 · DOI · Paper page
  34. Garbuzenko, 2022, Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease, Gastroenterol. Hepatol. Bed. Bench., 15, 194, 10.22037/ghfbb.v15i3.2549 · DOI
  35. Gilani, 2024, Adipose signals regulating distal organ health and disease, Diabetes, 73, 169, 10.2337/dbi23-0005 · DOI
  36. Gonzalez, 2020, Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD), Oxid. Med. Cell. Longev., 2020, 1617805, 10.1155/2020/1617805 · DOI
  37. Gumucio, 2019, Reduced mitochondrial lipid oxidation leads to fat accumulation in myosteatosis, FASEB J., 33, 7863, 10.1096/fj.201802457RR · DOI
  38. Habibullah, 2024, Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies, Front. Med. (Lausanne), 11, 1291501, 10.3389/fmed.2024.1291501 · DOI
  39. Hafiane, 2024, Adiponectin-mediated regulation of the adiponectin cascade in cardiovascular disease: updates, Biochem. Biophys. Res. Commun., 694, 149406, 10.1016/j.bbrc.2023.149406 · DOI
  40. Hallsworth, 2013, Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease, J. Hepatol., 58, 757, 10.1016/j.jhep.2012.11.015 · DOI
  41. Han, 2015, p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes, J. Am. Heart. Assoc., 4, e001852, 10.1161/JAHA.115.001852 · DOI
  42. Holecek, 2021, The role of skeletal muscle in the pathogenesis of altered concentrations of branched-chain amino acids (valine, leucine, and isoleucine) in liver cirrhosis, diabetes, and other diseases, Physiol. Res., 70, 293, 10.33549/physiolres.934648 · DOI
  43. Houghton, 2019, The degree of hepatic steatosis associates with impaired cardiac and autonomic function, J. Hepatol., 70, 1203, 10.1016/j.jhep.2019.01.035 · DOI
  44. Huang, 2022, Shared mechanisms between cardiovascular disease and NAFLD, Semin. Liver. Dis., 42, 455, 10.1055/a-1930-6658 · DOI
  45. Huang, 2023, Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk, Nutr. Metab. Cardiovasc. Dis., 33, 2479, 10.1016/j.numecd.2023.08.005 · DOI
  46. Ismaiel, 2019, Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review, Front. Med. (Lausanne), 6, 202, 10.3389/fmed.2019.00202 · DOI · Paper page
  47. Iwakiri, 2021, Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy, JHEP Rep., 3, 100316, 10.1016/j.jhepr.2021.100316 · DOI · Paper page
  48. Jacobs, 2014, Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database, J. Biomed. Res., 28, 349, 10.7555/JBR.28.20140045 · DOI
  49. Jensen, 2018, Fructose and sugar: a major mediator of non-alcoholic fatty liver disease, J. Hepatol., 68, 1063, 10.1016/j.jhep.2018.01.019 · DOI · Paper page
  50. Jia, 2024, Exercise alleviates aging of adipose tissue through adipokine regulation, Metabolites, 14, 135, 10.3390/metabo14030135 · DOI
  51. Jiang, 2024, Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics, Lipids. Health. Dis., 23, 95, 10.1186/s12944-024-02092-2 · DOI
  52. Jimenez, 2018, FGF21 gene therapy as treatment for obesity and insulin resistance, EMBO Mol. Med., 10, e8791, 10.15252/emmm.201708791 · DOI · Paper page
  53. Joo, 2023, Interaction between sarcopenia and nonalcoholic fatty liver disease, Clin. Mol. Hepatol., 29, S68, 10.3350/cmh.2022.0358 · DOI · Paper page
  54. Kang, 2023, Sarcopenic obesity, the possible culprit for nonalcoholic fatty liver disease or fibrosis, Gut. Liver., 17, 8, 10.5009/gnl220543 · DOI
  55. Kasper, 2021, NAFLD and cardiovascular diseases: a clinical review, Clin. Res. Cardiol., 110, 921, 10.1007/s00392-020-01709-7 · DOI · Paper page
  56. Katsiki, 2021, Serum uric acid and diabetes: from pathophysiology to cardiovascular disease, Curr. Pharm. Des., 27, 1941, 10.2174/1381612827666210104124320 · DOI
  57. Kawaguchi, 2023, Clinics in liver disease: update on nonalcoholic steatohepatitis: sarcopenia and nonalcoholic fatty liver disease, Clin. Liver. Dis., 27, 275, 10.1016/j.cld.2023.01.005 · DOI
  58. Khan, 2022, Non-alcoholic fatty liver disease and liver secretome, Arch. Pharm. Res., 45, 938, 10.1007/s12272-022-01419-w · DOI
  59. Kir, 2011, FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis, Science, 331, 1621, 10.1126/science.1198363 · DOI · Paper page
  60. Koplay, 2011, Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease, J. Investig. Med., 59, 1137, 10.2310/JIM.0b013e31822a29f5 · DOI
  61. Krishnan, 2014, IL-1beta and IL-18: inflammatory markers or mediators of hypertension?, Br. J. Pharmacol., 171, 5589, 10.1111/bph.12876 · DOI · Paper page
  62. Kumar, 2008, Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism, Cell. Metab., 8, 468, 10.1016/j.cmet.2008.10.011 · DOI · Paper page
  63. Lai, 2021, Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases, Hepatol., 74, 1611, 10.1002/hep.32049 · DOI · Paper page
  64. Lebeaupin, 2018, Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease, J. Hepatol., 69, 927, 10.1016/j.jhep.2018.06.008 · DOI · Paper page
  65. Lee, 1999, Myostatin and the control of skeletal muscle mass, Curr. Opin. Genet. Dev., 9, 604, 10.1016/s0959-437x(99)00004-0 · DOI · Paper page
  66. Lee, 2015, Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011), J. Hepatol., 63, 486, 10.1016/j.jhep.2015.02.051 · DOI · Paper page
  67. Lee, 2018, Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients, J. Hepatol., 68, 764, 10.1016/j.jhep.2017.11.023 · DOI
  68. Levy, 2021, Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients, Am. J. Clin. Nutr., 113, 1157, 10.1093/ajcn/nqaa432 · DOI
  69. Li, 2011, Leptin and beyond: an odyssey to the central control of body weight, Yale J. Biol. Med., 84, 1
  70. Li, 2023, Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH), Kidney. Int., 105, 540, 10.1016/j.kint.2023.12.009 · DOI
  71. Lim, 2019, Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome, Obes. Rev., 20, 599, 10.1111/obr.12820 · DOI
  72. Lim, 2023, Natural history of NASH cirrhosis in liver transplant waitlist registrants, J. Hepatol., 79, 1015, 10.1016/j.jhep.2023.05.034 · DOI
  73. Linton, 2000, Endotext
  74. Liu, 2015, The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy, Metabolism, 64, 380, 10.1016/j.metabol.2014.11.009 · DOI
  75. Llovet, 2023, Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment, Nat. Rev. Gastroenterol. Hepatol., 20, 487, 10.1038/s41575-023-00754-7 · DOI · Paper page
  76. Ludwig, 1980, Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin. Proc., 55, 434, 10.1016/S0025-6196(24)00530-5 · DOI · Paper page
  77. Lundberg, 2021, Idiopathic inflammatory myopathies, Nat. Rev. Dis. Prim., 7, 86, 10.1038/s41572-021-00321-x · DOI · Paper page
  78. Machado, 2021, Aerobic exercise in the management of metabolic dysfunction associated fatty liver disease, Diabetes Metab. Syndr. Obes., 14, 3627, 10.2147/DMSO.S304357 · DOI
  79. Machado, 2016, Pathogenesis of nonalcoholic steatohepatitis, Gastroenterol., 150, 1769, 10.1053/j.gastro.2016.02.066 · DOI · Paper page
  80. Mahamid, 2018, Folate and B12 levels correlate with histological severity in NASH patients, Nutrients, 10, 440, 10.3390/nu10040440 · DOI
  81. Mahmoudi, 2024, Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches, Eur. J. Med. Res., 29, 190, 10.1186/s40001-024-01708-8 · DOI
  82. Mantovani, 2022, Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week, J. Am. Coll. Cardiol., 79, 180, 10.1016/j.jacc.2021.11.007 · DOI
  83. Mantovani, 2019, Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis, Liver. Int., 39, 758, 10.1111/liv.14044 · DOI
  84. Marcuccilli, 2016, NAFLD and chronic kidney disease, Int. J. Mol. Sci., 17, 562, 10.3390/ijms17040562 · DOI · Paper page
  85. Medrano-Bosch, 2023, Monocyte-endothelial cell interactions in vascular and tissue remodeling, Front. Immunol., 14, 1196033, 10.3389/fimmu.2023.1196033 · DOI
  86. Meijers, 2010, p-Cresol and cardiovascular risk in mild-to-moderate kidney disease, Clin. J. Am. Soc. Nephrol., 5, 1182, 10.2215/CJN.07971109 · DOI · Paper page
  87. Mendez-Sanchez, 2020, Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis, F1000Res, 9, 56, 10.12688/f1000research.21918.1 · DOI
  88. Meng, 2016, Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population, Sci. Rep., 6, 33255, 10.1038/srep33255 · DOI
  89. Meyer, 2020, Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis, Int. J. Mol. Sci., 21, 5357, 10.3390/ijms21155357 · DOI
  90. Misu, 2010, A liver-derived secretory protein, selenoprotein P, causes insulin resistance, Cell Metab., 12, 483, 10.1016/j.cmet.2010.09.015 · DOI · Paper page
  91. Mitten, 2022, Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease, J. Hepatol., 77, 1642, 10.1016/j.jhep.2022.08.028 · DOI
  92. Mohammed, 2014, Right ventricular function in heart failure with preserved ejection fraction: a community-based study, Circulation, 130, 2310, 10.1161/CIRCULATIONAHA.113.008461 · DOI · Paper page
  93. Mounier, 2013, AMPKα1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration, Cell. Metab., 18, 251, 10.1016/j.cmet.2013.06.017 · DOI · Paper page
  94. Murthy, 2011, Improved cardiac risk assessment with noninvasive measures of coronary flow reserve, Circulation, 124, 2215, 10.1161/CIRCULATIONAHA.111.050427 · DOI · Paper page
  95. Musa-Veloso, 2018, Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease, Nutr. Rev., 76, 581, 10.1093/nutrit/nuy022 · DOI
  96. Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS. Med., 11, e1001680, 10.1371/journal.pmed.1001680 · DOI · Paper page
  97. Muzurovic, 2022, Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors, Hypertension, 79, 1319, 10.1161/HYPERTENSIONAHA.122.17982 · DOI
  98. Nahandi, 2014, Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis, Gastroenterol. Hepatol. Bed. Bench., 7, 55
  99. Njoku, 2022, Mechanisms of nonalcoholic steatohepatitis-associated cardiomyopathy: key roles for liver-heart crosstalk, Curr. Opin. Lipidol., 33, 295, 10.1097/MOL.0000000000000845 · DOI
  100. Nogal, 2021, The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health, Gut. Microbes., 13, 1, 10.1080/19490976.2021.1897212 · DOI · Paper page
  101. Pais, 2019, Relationship among fatty liver, specific and multiple-site atherosclerosis, and 10-year framingham score, Hepatol., 69, 1453, 10.1002/hep.30223 · DOI
  102. Pasceri, 2000, Direct proinflammatory effect of C-reactive protein on human endothelial cells, Circulation, 102, 2165, 10.1161/01.cir.102.18.2165 · DOI · Paper page
  103. Patel, 2019, The interplay between nonalcoholic fatty liver disease and atherosclerotic heart disease, Hepatol., 69, 1372, 10.1002/hep.30410 · DOI · Paper page
  104. Peng, 2020, Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments, Front. Pharmacol., 11, 603926, 10.3389/fphar.2020.603926 · DOI · Paper page
  105. Peng, 2022, Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study, Metabolism, 133, 155220, 10.1016/j.metabol.2022.155220 · DOI
  106. Perdomo, 2021, Role of ANGPTL8 in NAFLD improvement after bariatric surgery in experimental and human obesity, Int. J. Mol. Sci., 22, 12945, 10.3390/ijms222312945 · DOI
  107. Peter, 2018, The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans, Am. J. Physiol. Endocrinol. Metab., 314, E266, 10.1152/ajpendo.00262.2017 · DOI
  108. Petta, 2015, Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease, J. Hepatol., 62, 928, 10.1016/j.jhep.2014.11.030 · DOI · Paper page
  109. Petta, 2017, Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease, Aliment. Pharmacol. Ther., 45, 510, 10.1111/apt.13889 · DOI · Paper page
  110. Philips, 2020, Modulating the intestinal microbiota: therapeutic opportunities in liver disease, J. Clin. Transl. Hepatol., 8, 87, 10.14218/JCTH.2019.00035 · DOI
  111. Pillon, 2013, Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications, Am. J. Physiol. Endocrinol. Metab., 304, E453, 10.1152/ajpendo.00553.2012 · DOI · Paper page
  112. Plomgaard, 2022, GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans, Front. Endocrinol. (Lausanne), 13, 1037948, 10.3389/fendo.2022.1037948 · DOI
  113. Pouwels, 2022, Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss, BMC Endocr. Disord., 22, 63, 10.1186/s12902-022-00980-1 · DOI · Paper page
  114. Powell, 2021, Non-alcoholic fatty liver disease, Lancet, 397, 2212, 10.1016/S0140-6736(20)32511-3 · DOI · Paper page
  115. Purnamasari, 2022, Sarcopenia and chronic complications of type 2 diabetes mellitus, Rev. Diabet. Stud., 18, 157, 10.1900/RDS.2022.18.157 · DOI
  116. Rafaqat, 2024, Interleukins: pathogenesis in non-alcoholic fatty liver disease, Metabolites, 14, 153, 10.3390/metabo14030153 · DOI
  117. Raghow, 2013, Betatrophin: a liver-derived hormone for the pancreatic β-cell proliferation, World J. Diabetes., 4, 234, 10.4239/wjd.v4.i6.234 · DOI
  118. Ratchford, 2014, Carotid artery disease, Vasc. Med., 19, 512, 10.1177/1358863X14557722 · doi:10.1177/1358863x14557722
  119. Ren, 2023, Relationship between NAFLD and coronary artery disease: a Mendelian randomization study, Hepatol., 77, 230, 10.1002/hep.32534 · DOI
  120. Ribeiro, 2023, Uremic toxin indoxyl sulfate promotes macrophage-associated low-grade inflammation and epithelial cell senescence, Int. J. Mol. Sci., 24, 8031, 10.3390/ijms24098031 · DOI
  121. Roman, 2014, Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis, Dig. Dis. Sci., 59, 1966, 10.1007/s10620-014-3086-6 · DOI · Paper page
  122. Salah, 2021, Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction, JACC Basic Transl. Sci., 6, 918, 10.1016/j.jacbts.2021.07.010 · DOI
  123. Santilli, 2014, Clinical definition of sarcopenia, Clin. Cases Min. Bone. Metab., 11, 177
  124. Schober, 2008, Chemokines in vascular dysfunction and remodeling, Arterioscler. Thromb. Vasc. Biol., 28, 1950, 10.1161/ATVBAHA.107.161224 · DOI · Paper page
  125. Semmler, 2021, Diet and exercise in NAFLD/NASH: beyond the obvious, Liver. Int., 41, 2249, 10.1111/liv.15024 · DOI · Paper page
  126. Seo, 2021, Hepatokines as a molecular transducer of exercise, J. Clin. Med., 10, 385, 10.3390/jcm10030385 · DOI
  127. Sethi, 2021, Metabolic Messengers: tumour necrosis factor, Nat. Metab., 3, 1302, 10.1038/s42255-021-00470-z · DOI · Paper page
  128. Shimada, 2004, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism, J. Clin. Invest., 113, 561, 10.1172/JCI19081 · doi:10.1172/jci19081 · Paper page
  129. Siddiqui, 2015, Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile, Clin. Gastroenterol. Hepatol., 13, 1000, 10.1016/j.cgh.2014.10.008 · DOI · Paper page
  130. Simons, 2022, Association between de novo lipogenesis susceptibility genes and coronary artery disease, Nutr. Metab. Cardiovasc. Dis., 32, 2883, 10.1016/j.numecd.2022.09.003 · DOI
  131. Sinha, 2018, Direct effects of thyroid hormones on hepatic lipid metabolism, Nat. Rev. Endocrinol., 14, 259, 10.1038/nrendo.2018.10 · DOI · Paper page
  132. Solanki, 2023, Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration, Front. Neurol., 14, 1149618, 10.3389/fneur.2023.1149618 · DOI · Paper page
  133. Song, 2022, The role of gut-liver Axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC, Biomedicines, 10, 524, 10.3390/biomedicines10030524 · DOI
  134. Stasi, 2022, Obesity-related chronic kidney disease: principal mechanisms and new approaches in nutritional management, Front. Nutr., 9, 925619, 10.3389/fnut.2022.925619 · DOI
  135. Stefan, 2023, The role of hepatokines in NAFLD, Cell. Metab., 35, 236, 10.1016/j.cmet.2023.01.006 · DOI · Paper page
  136. Su, 2023, Atherosclerosis: the involvement of immunity, cytokines and cells in pathogenesis, and potential novel therapeutics, Aging. Dis., 14, 1214, 10.14336/AD.2022.1208 · DOI
  137. Sunaga, 2019, Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: role of adrenergic overdrive and lipolysis byproducts, Sci. Rep., 9, 11841, 10.1038/s41598-019-48356-1 · DOI
  138. Sveinbjornsson, 2022, Multiomics study of nonalcoholic fatty liver disease, Nat. Genet., 54, 1652, 10.1038/s41588-022-01199-5 · DOI · Paper page
  139. Tang, 2022, Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: an updated meta-analysis with 135,602 individuals, Clin. Mol. Hepatol., 28, 483, 10.3350/cmh.2021.0406 · DOI
  140. Taqueti, 2018, Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction, Eur. Heart J., 39, 840, 10.1093/eurheartj/ehx721 · DOI · Paper page
  141. Targher, 2006, Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease, Diabetes Care, 29, 1325, 10.2337/dc06-0135 · DOI · Paper page
  142. Targher, 2024, MASLD: a systemic metabolic disorder with cardiovascular and malignant complications, Gut, 73, 691, 10.1136/gutjnl-2023-330595 · DOI · Paper page
  143. Tilg, 2021, Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity, Nat. Metab., 3, 1596, 10.1038/s42255-021-00501-9 · DOI · Paper page
  144. Tripathi, 2022, Vitamin B(12) and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation, J. Hepatol., 77, 1246, 10.1016/j.jhep.2022.06.033 · DOI
  145. Umbro, 2021, Nonalcoholic fatty liver disease and the kidney: a review, Biomedicines, 9, 1370, 10.3390/biomedicines9101370 · DOI
  146. Valenzuela-Vallejo, 2023, Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a Multicenter Observational Study, Metabolism, 148, 155694, 10.1016/j.metabol.2023.155694 · DOI
  147. van der Meer, Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men, J. Clin. Endocrinol. Metab., 93, 2702, 10.1210/jc.2007-2524 · DOI · Paper page
  148. van der Meer, The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function, Eur. Heart J., 29, 1516, 10.1093/eurheartj/ehn207 · DOI
  149. VanWagner, 2018, New insights into NAFLD and subclinical coronary atherosclerosis, J. Hepatol., 68, 890, 10.1016/j.jhep.2018.01.023 · DOI
  150. Venkatesh, 2024, Shrinking fat, healing liver: unlocking the metabolic dysfunction associated steatohepatitis puzzle, Hepatobiliary Surg. Nutr., 13, 132, 10.21037/hbsn-23-569 · DOI
  151. Venniyoor, 2021, The troubling link between non-alcoholic fatty liver disease (NAFLD) and extrahepatic cancers (EHC), Cureus, 13, e17320, 10.7759/cureus.17320 · DOI
  152. Verma Mkt, 2024, Dietary determinants of metabolic syndrome: focus on the obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), 1, 10.5772/intechopen.114832 · DOI
  153. Villanova, 2005, Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease, Hepatol., 42, 473, 10.1002/hep.20781 · DOI · Paper page
  154. Violi, 2023, Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease, Nat. Rev. Cardiol., 20, 24, 10.1038/s41569-022-00737-2 · DOI · Paper page
  155. Viveiros, 2021, The role of life style modifications in comprehensive non-alcoholic fatty liver disease treatment, Clin. Liver. Dis. Hob., 17, 11, 10.1002/cld.1007 · DOI
  156. Walker, 2014, Ammonia metabolism and hyperammonemic disorders, Adv. Clin. Chem., 67, 73, 10.1016/bs.acc.2014.09.002 · DOI · Paper page
  157. Wang, 2024, Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease, Hepatol. Int., 18, 943, 10.1007/s12072-023-10624-8 · DOI
  158. Wang, 2022, Association of metabolic dysfunction-associated fatty liver disease with kidney disease, Nat. Rev. Nephrol., 18, 259, 10.1038/s41581-021-00519-y · DOI · Paper page
  159. Wang, 2013, Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland, Heart, 99, 163, 10.1136/heartjnl-2012-302972 · DOI
  160. Wannamethee, 2012, Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men, Arterioscler. Thromb. Vasc. Biol., 32, 830, 10.1161/ATVBAHA.111.240457 · DOI
  161. Wegermann, 2023, Serum metabolites are associated with HFpEF in biopsy-proven nonalcoholic fatty liver disease, J. Am. Heart Assoc., 12, e029873, 10.1161/JAHA.123.029873 · DOI
  162. Wijarnpreecha, 2019, Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA, Eur. J. Gastroenterol. Hepatol., 31, 1121, 10.1097/MEG.0000000000001397 · DOI
  163. Witkowski, 2022, The economic burden of non-alcoholic steatohepatitis: a systematic review, Pharmacoeconomics, 40, 751, 10.1007/s40273-022-01140-y · DOI
  164. Wong, 2023, Changing epidemiology, global trends and implications for outcomes of NAFLD, J. Hepatol., 79, 842, 10.1016/j.jhep.2023.04.036 · DOI · Paper page
  165. Xiang, 2022, The role of the intestinal microbiota in nonalcoholic steatohepatitis, Front. Endocrinol. (Lausanne), 13, 812610, 10.3389/fendo.2022.812610 · DOI
  166. Xie, 2023, The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study, Hepatol., 77, 949, 10.1002/hep.32728 · DOI · Paper page
  167. Yadav, 2013, Role of leptin and adiponectin in insulin resistance, Clin. Chim. Acta., 417, 80, 10.1016/j.cca.2012.12.007 · DOI · Paper page
  168. Yan, 2023, Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study, BMJ Open, 13, e072489, 10.1136/bmjopen-2023-072489 · DOI
  169. Yang, 2023, Coronary microvascular dysfunction and cardiovascular disease: pathogenesis, associations and treatment strategies, Biomed. Pharmacother., 164, 115011, 10.1016/j.biopha.2023.115011 · DOI
  170. Yang, 2022, Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction, Front. Cardiovasc. Med., 9, 1120085, 10.3389/fcvm.2022.1120085 · DOI
  171. Yarasheski, 2002, Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting, J. Nutr. Health. Aging., 6, 343
  172. Yoshida, 2020, Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy, Cells, 9, 1970, 10.3390/cells9091970 · DOI · Paper page
  173. Younossi, Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa, Liver. Int., 44, 1061, 10.1111/liv.15852 · DOI
  174. Younossi, Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease, J. Hepatol., 80, 694, 10.1016/j.jhep.2024.01.014 · DOI · Paper page
  175. Younossi, The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease, Hepatol. Commun., 8, e0352, 10.1097/HC9.0000000000000352 · DOI
  176. Yu, 2022, A pooled analysis of the association between sarcopenia and osteoporosis, Med. Baltim., 101, e31692, 10.1097/MD.0000000000031692 · DOI
  177. Zaric, 2019, Homocysteine and hyperhomocysteinaemia, Curr. Med. Chem., 26, 2948, 10.2174/0929867325666180313105949 · DOI · Paper page
  178. Zegeye, 2018, Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells, Cell. Commun. Signal., 16, 55, 10.1186/s12964-018-0268-4 · DOI · Paper page
  179. Zeng, 2024, Therapeutic management of metabolic dysfunction associated steatotic liver disease, United Eur. Gastroenterol. J., 12, 177, 10.1002/ueg2.12525 · DOI
  180. Zhang, 2024, Bacteroides and NAFLD: pathophysiology and therapy, Front. Microbiol., 15, 1288856, 10.3389/fmicb.2024.1288856 · DOI
  181. Zhang, 2019, A review of fibroblast growth factor 21 in diabetic cardiomyopathy, Heart Fail Rev., 24, 1005, 10.1007/s10741-019-09809-x · DOI
  182. Zhang, 2022, The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study, Eur. J. Med. Res., 27, 307, 10.1186/s40001-022-00958-8 · DOI
  183. Zhang, 2023, PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: a network meta-analysis, J. Int. Med. Res., 51, 3000605231177191, 10.1177/03000605231177191 · DOI
  184. Zhao, TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients, Cardiovasc. Diabetol., 21, 123, 10.1186/s12933-022-01548-y · DOI · Paper page
  185. Zhao, New insights into fibrosis from the ECM degradation perspective: the macrophage-MMP-ECM interaction, Cell Biosci., 12, 117, 10.1186/s13578-022-00856-w · DOI · Paper page
  186. Zhen, 2023, The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases, Front. Endocrinol. (Lausanne), 14, 1085041, 10.3389/fendo.2023.1085041 · DOI · Paper page
  187. Zhu, 2023, Two sides of the same coin: non-alcoholic fatty liver disease and atherosclerosis, Vasc. Pharmacol., 154, 107249, 10.1016/j.vph.2023.107249 · DOI
  188. Zhu, 2021, Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis, Front. Endocrinol. (Lausanne), 12, 769069, 10.3389/fendo.2021.769069 · DOI

Cited by

See all 211

Metadata

Authors
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K.
Venue
Frontiers in Cell and Developmental Biology
Published
2024-07-16
Volume
12
Pages
1433857-1433857
ISSN
2296-634X (ISSN-L)
OpenAlex
W4400696056
Cited by
211
References
36
FWCI
55.17
Type
journal article
Language
en
Open access
gold
Funders
National Medical Research Council (MOH-OFIRG19may-0002 Duke-NUS-KBrFA/2023/0075)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. https://app.cochat.ai/papers/10.3389/fcell.2024.1433857
The paper
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024). Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2024.1433857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.